Walleye Capital LLC Has $219,000 Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Walleye Capital LLC reduced its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWRGet Rating) by 73.6% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 6,213 shares of the biotechnology company’s stock after selling 17,330 shares during the period. Walleye Capital LLC’s holdings in Arrowhead Pharmaceuticals were worth $219,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in ARWR. Comerica Bank increased its stake in shares of Arrowhead Pharmaceuticals by 5.0% in the 1st quarter. Comerica Bank now owns 48,333 shares of the biotechnology company’s stock valued at $2,211,000 after buying an additional 2,281 shares during the period. Mutual of America Capital Management LLC increased its stake in shares of Arrowhead Pharmaceuticals by 0.7% in the 1st quarter. Mutual of America Capital Management LLC now owns 142,328 shares of the biotechnology company’s stock valued at $6,546,000 after buying an additional 925 shares during the period. Banque Pictet & Cie SA increased its stake in shares of Arrowhead Pharmaceuticals by 0.5% in the 1st quarter. Banque Pictet & Cie SA now owns 167,970 shares of the biotechnology company’s stock valued at $7,725,000 after buying an additional 880 shares during the period. Pictet & Cie Europe SA grew its stake in shares of Arrowhead Pharmaceuticals by 10.9% during the first quarter. Pictet & Cie Europe SA now owns 8,203 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 808 shares during the period. Finally, Victory Capital Management Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 26.2% during the first quarter. Victory Capital Management Inc. now owns 46,247 shares of the biotechnology company’s stock worth $1,901,000 after purchasing an additional 9,610 shares during the period. 67.29% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Up 0.5 %

NASDAQ:ARWR opened at $30.72 on Friday. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $26.81 and a 1 year high of $74.77. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.16. The stock has a market cap of $3.25 billion, a price-to-earnings ratio of -20.76 and a beta of 1.42. The stock has a 50-day moving average price of $33.28 and a two-hundred day moving average price of $36.50.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ARWR. Piper Sandler decreased their price objective on Arrowhead Pharmaceuticals from $72.00 to $64.00 and set an “overweight” rating for the company in a research note on Wednesday, November 9th. SVB Leerink lifted their price objective on Arrowhead Pharmaceuticals from $32.00 to $33.00 and gave the stock a “market perform” rating in a research note on Thursday, November 10th. Chardan Capital lifted their price objective on Arrowhead Pharmaceuticals from $80.00 to $82.00 in a research note on Friday, August 5th. Morgan Stanley began coverage on Arrowhead Pharmaceuticals in a research note on Friday, September 9th. They set an “equal weight” rating and a $41.00 price objective for the company. Finally, StockNews.com started coverage on Arrowhead Pharmaceuticals in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $65.00.

About Arrowhead Pharmaceuticals

(Get Rating)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma.

Further Reading

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.